On Monday, Genedrive (LON: GDR) announced £6m of equity funding, including £3m from two major shareholders – David Nugent and Robert English. There will be an open offer of up to £2m. The cash will finance commercialisation and refinements of tests, as well as an FDA submission. The funding share price has not been set, and the current price has rebounded 29.7% to 1.2p.
Water mediation services provider MYCELX Technologies (LON: MYX) grew 2025 revenues by 1405 to $11.7m and this, along with cost controls, has enabled the company to achieve an expected profit of around $360,000. A loss was previously forecast. The share price improved 15.8% to 33p.
Loyalty platform provider Eagle Eye (LON: EYE) did better than expected in the first half with underlying growth in revenues of 16% to £22.4m, although the previously announced lost contract meant that the reported figure is 5% lower. Annualised recurring revenues were higher at £42.2m due to contract wins. EBITDA fell from £5.9m to £4.3m. A small full year pre-tax profit is now forecast. The share price increased 15.4% to 345p.
Thruvision (LON: THRU) has won a South East Asia mass transit contract, which should generate £1m in revenues. This is for 20 Thruvision high-throughput people-screening systems. The share price rose 10.5% to 1.05p.
Staffline (LON: STAF) did significantly better than expected in 2025 and is estimated to have moved from debt to net cash of £1.5m at the end of the year. The staffing company improved pre-tax profit 42% to £7.1m – previously estimated at £6m. Ireland had a strong second half and the UK did well in the Christmas period. Panmure Liberum has raised its 2026 pre-tax profit forecast from £8.3m to £9.2m. The share price moved up 10.3% to 49.3p.
FALLERS
CPP Group (LON: CPP) is reviewing its AIM quotation. The company has disposed of non-core operations to focus on InsurTech and the chief executive of the Blink InsurTech business has been appointed to the CPP board. Leaving AIM would reduce costs and improve flexibility for the business. Blink continues to grow and there are £5.6m in the bank at the end of 2025. There are deferred payments of up to £5.7m due in 2027. The share price slumped 38% to 50.5p.
PetroTal Corp (LON: PTAL) is targeting average 2026 production of 11,750-12,250 barrels of oil per day. There will be capital investment of up to $90m during the year, predominantly on the Bretana field in Peru. A third party drilling contractor will be used. Annual adjusted EBITDA is expected to be $30m at $60/barrel after erosion control expenses. The share price declined 20.5% to 17.5p.
Kromek (LON: KMK) moved from loss to profit in the first half. In the six months to October 2025, revenues jumped from £3.7m to £15m due to a large payment from Siemens Healthineers for imaging technology expertise. Advanced imaging revenues were higher even if that payment is excluded. The CBRN detection division more than doubled revenues. Cavendish is maintaining its full year forecasts with more modest full year growth of revenues from £26.5m to £27.1m, which reflects the second half payment from Siemens last year. The underlying growth of the rest of the business continues. Forecast pre-tax profit is £2.3m. The share price has soared in the past six months. The share price dipped 12.8% to 10.025p, which is still double the share price at the beginning of 2025.
Flowtech Fluidpower (LON: FLO) has launched a £9m placing and a retail offer of up to £1m at 53p/share. The cash will be used to fund the acquisition of pneumatic and compressed air products suppliers Q Plus and Naili Europe in the Netherlands and reduced debt. The total cost of the acquisition is €5.87m, including cash of €4.12m and intercompany debt of €1.96m will be repaid. In 2025, the existing group revenues were nearly 10% ahead at £116.9m. Net debt was £15.4m. The retail offer closes on 22 January. The share price fell 6.51% to 56p.